Objective Capital Management’s Edwards Lifesciences EW Stock Holding History

Objective Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$812K	Hold	9,410	–	–	0.73%	35
2026 Q2	$851K	Sell	9,410 -375	-4%	-$31.4K	0.76%	36
2026 Q1	$784K	Buy	9,785 +723	+8%	+$59.6K	0.79%	41
2025 Q4	$773K	Sell	9,062 -750	-8%	-$61.6K	0.79%	37
2025 Q3	$763K	Sell	9,812 -200	-2%	-$15.6K	0.79%	33
2025 Q2	$783K	Buy	10,012 +37	+0.4%	+$2.76K	0.88%	31
2025 Q1	$723K	Sell	9,975 -100	-1%	-$7.16K	0.92%	30
2024 Q4	$746K	Sell	10,075 -35	-0.3%	-$2.45K	0.5%	48
2024 Q3	$667K	Buy	+10,110	New	+$735K	0.39%	59
2024 Q1	$979K	Buy	10,245 +10	+0.1%	+$840	0.66%	39
2023 Q4	$780K	Buy	10,235 +10	+0.1%	+$696	0.59%	40
2023 Q3	$708K	Sell	10,225 -72	-0.7%	-$5.79K	0.63%	39
2023 Q2	$971K	Hold	10,297	–	–	0.85%	36
2023 Q1	$852K	Hold	10,297	–	–	0.78%	36
2022 Q4	$768K	Hold	10,297	–	–	0.76%	37
2022 Q3	$851K	Hold	10,297	–	–	0.91%	34
2022 Q2	$979K	Sell	10,297 -75	-0.7%	-$7.76K	0.99%	31
2022 Q1	$1.22M	Hold	10,372	–	–	0.94%	28
2021 Q4	$1.34M	Buy	+10,372	New	+$1.21M	0.95%	27

Other funds holding EW

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Ninety One Cape Town, South Africa $2B AUM 34.6% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Objective Capital Management's EW Position: Q3 2026 in Review

Objective Capital Management held its Edwards Lifesciences (EW) position steady in Q3 2026 at 9,410 shares worth $812K. The position accounts for 0.73% of the portfolio, ranked #35.

Objective Capital Management first reported a position in EW in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.34M in Q4 2021. 258 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Objective Capital Management held 9,410 shares of Edwards Lifesciences worth $812K as of Q3 2026.
Objective Capital Management left its Edwards Lifesciences share count unchanged in Q3 2026.
Edwards Lifesciences made up 0.73% of Objective Capital Management's portfolio in Q3 2026, its #35 holding.
Objective Capital Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 19 quarters since.
Objective Capital Management's Edwards Lifesciences position peaked at $1.34M in Q4 2021.
258 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Objective Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.